Pillar® ONCO/Reveal™ Multi-Cancer Panel
The ONCO/Reveal Multi-Cancer Panel is a robust NGS assay that interrogates 56 genes of interest across multiple solid tumor cancer types. The assay uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
Panel highlights
Requires as little as 2.5 ng of input DNA
Targets >7,200 hotspots in multiple solid tumor types
Detection of 1% allele frequency in somatic cancers
From sample to library in as little as 5 hours (2 hrs hands on)
For research use only. Not for use in diagnostic procedures.
Panel targets
| ABL1 | CSF1R | FGFR1 | HNF1A | KRAS | NTRK1 | ROS1 |
| AKT1 | CTNNB1 | FGFR2 | HRAS | MAP2K1 | PDGFRA | SMAD4 |
| ALK | DDR2 | FGFR3 | IDH1 | MET | PIK3CA | SMARCB1 |
| APC | EGFR | FLT3 | IDH2 | MLH1 | PTEN | SMO |
| ATM | ERBB2 | FOXL2 | JAK2 | MPL | PTPN11 | SRC |
| BRAF | ERBB4 | GNA11 | JAK3 | NOTCH1 | RAC1 | STK11 |
| CDH1 | EZH2 | GNAQ | KDR | NPM1 | RB1 | TP53 |
| CDKN2A | FBXW7 | GNAS | KIT | NRAS | RET | VHL |
Panel specifications
| Enrichment chemistry | Multiplex PCR using tiled amplicons |
| Number of pools | 1 pool |
| Number of genes/amplicons | 56/251 |
| Number of targets | >7,200 hotspots, 6,000 SNVs, 1,200 indels, 24kb total size |
| Variant types | SNVs, indels |
| Average amplicon size | 143bp |
| Recommended DNA input range | 5ng to 80ng |
| Sample types | DNA from tissue or blood; cfDNA; FFPE |
| Mapping rate | 99.8% ± 0.0% |
| % on-target aligned reads | 96.2% ± 0.1% |
| Coverage uniformity (% targets with >0.2X mean coverage) | 96.1 ± 0.1% |
| Total assay time (from DNA to sequencer) | <8 hours |
| Sequencing platforms | Illumina® and MGISEQ™ |
See the data
AMP 2018- Tumor Poster
Single-vial Amplification Based NGS with Rapid Turn-Around-Time for Interrogation of Variants in Tumors
ASCO 2018 - Breast Cancer Poster
Clinical and biomarker results from Phase I-II study of PI3K inhibitor BYL719 (Apelisib) plus Nab-paclitaxel in HER2-negative Metastatic Breast Cancer
AMP 2017 - Cancer Hotspot Poster
Evaluation of the Pillar NGS SLIMap Cancer Hotspot Panel
Sensitive variant detection
The ONCO/Reveal Multi-Cancer Panel demonstrated high sensitivity and concordance across the range of allele frequencies.
| Variant | # samples | VAF range (%) |
|---|---|---|
| BRAF V600E | 4 | 1.6 - 44 |
| BRAF Other | 2 | 5 |
| EGFR exon19 deletion | 7 | 1.4 - 42 |
| EGFR exon 20 insertion | 2 | 18 - 22 |
| EGFR L858R | 4 | 16 - 80 |
| EGFR T790M | 2 | 3 - 10 |
| KRAS G12A/C/D/F/S/V | 15 | 6 - 33 |
| KRAS G12R | 1 | 28 |
| KRAS K117 | 1 | 16 |
| KIT exon11 deletion | 2 | 35, 63 |
| MET exon14 skipping | 2 | 72, 75 |
| NRAS Q61K/R | 2 | 40, 80 |
| NRAS G12C | 1 | 38 |
| PIK3CA E545K/H1047R | 2 | 6, 36 |
| STK11 missense | 2 | 35, 28 |
| STK11 deletion | 1 | 20 |
| TP53 nonsense | 5 | 21 |
Concordance demonstrated with low DNA inputs
Dive straight into the feedback!Login below and you can start commenting using your own user instantly